Premium
Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X
Author(s) -
IdziorWalus B.,
Sieradzki J.,
Rostworowski W.,
Zdzienicka A.,
Kawalec E.,
Wójcik J.,
Żarnecki A.,
Blane G.
Publication year - 2000
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1046/j.1365-2362.2000.00734.x
Subject(s) - fenofibrate , medicine , endocrinology , dyslipidemia , triglyceride , metabolic syndrome , insulin , lipid profile , blood pressure , uric acid , insulin resistance , cholesterol , fibrinogen , diabetes mellitus
Background This study investigated the effects of comicronised fenofibrate in patients with dyslipidemia and polymetabolic syndrome X. Design After a 6‐week dietary run‐in phase, 37 male patients eligible on lipid criteria entered a 12‐week treatment phase consisting of diet plus one capsule daily containing 200 mg of comicronised fenofibrate (Lipanthyl ® ). Results A significant reduction in plasma concentrations of total cholesterol, LDL cholesterol and triglyceride was observed after 4, 8 and 12 weeks of treatment with fenofibrate. The improvement in the atherogenic index LDL/HDL cholesterol from a pretreatment 3.8 to 3.0 after treatment was highly statistically significant and may be judged as satisfactory. Significant changes were also observed in haemostatic factors (fibrinogen reduced by 19%, factor VII activity reduced by 18%). Fasting serum insulin levels and insulin response (area under the curve) after oral glucose load were significantly reduced by 26.8% and 18.7%, respectively, indicating an improvement of insulin sensitivity. Systolic and diastolic blood pressure were significantly reduced. Uric acid was significantly reduced by 21.6%. Conclusion These favourable effects of comicronised fenofibrate both on lipid and non lipid parameters, including insulin sensitivity, may confer to this product a particular interest in the treatment of patients with polymetabolic syndrome X.